Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
    • Corporate Responsibility

    • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • Sudocetaxel zendusortide (TH1902)
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs

    • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs

    • Careers

  • Careers

    • Contact Us

  • Contact Us
  • en
    • en
    • fr

    • btn Alerts

  • Sign up for Email Alerts

Social icons

News

Investors

IR Nav

  • Overview
  • News, Events & Presentations
    • Press Releases
    • Company Announcements
    • Events
    • Corporate Presentations
  • Stock Information
    • Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • SEDAR Filings
    • Financial Reports
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Investor Resources
    • Contact IR
    • FAQs

Stock

Prices shown in CAD

Dec 22, 2024 1:30 AM EST

btn Stock

Learn More

IR Tools

  • Email Alerts
  • Contact IR
  • RSS Feeds

THERATECHNOLOGIES TO ANNOUNCE FINANCIAL RESULTS FOR THIRD QUARTER 2018

Sep 27, 2018
PDF Version
Supporting Materials:
THERATECHNOLOGIES TO ANNOUNCE FINANCIAL RESULTS FOR THIRD QUARTER 2018 137.4 KB

Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2018, on Thursday, October 4, 2018.

Headquarters

Theratechnologies inc.
2015 Peel Street, 11th Floor
Montréal, Québec
Canada H3A 1T8
Phone: 514 336-7800
Fax: 514 331-9691

European Headquarters

Theratechnologies Europe Limited
1st Floor, 12 Duke Lane Upper
Royal Hibernian Way
DUBLIN
Dublin 2
Ireland D02 DX07
Phone: +353 1 215 0650
europe@theratech.com

Investor Relations

Philippe Dubuc
Senior Vice President and Chief Financial Officer
Phone: +1-438-315-6608
ir@theratech.com

US Headquarters

Theratechnologies U.S., Inc.
101 Hudson Street
21st Floor
Jersey City, New Jersey 07302

Main Nav

  • Home
  • About
  • Medicines & Pipeline
  • Investors
  • Careers
  • Contact Us
©2024 - Theratechnologies Inc.

Legal Nav

  • Terms of Use
  • Privacy

Search

Theratechnologies